WO2002056755A3 - Method for treating cancer - Google Patents

Method for treating cancer Download PDF

Info

Publication number
WO2002056755A3
WO2002056755A3 PCT/US2002/000943 US0200943W WO02056755A3 WO 2002056755 A3 WO2002056755 A3 WO 2002056755A3 US 0200943 W US0200943 W US 0200943W WO 02056755 A3 WO02056755 A3 WO 02056755A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
treating cancer
followed
formula
administration
Prior art date
Application number
PCT/US2002/000943
Other languages
French (fr)
Other versions
WO2002056755A2 (en
Inventor
Frederick H Hausheer
Original Assignee
Bionumerik Pharmaceuticals Inc
Frederick H Hausheer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc, Frederick H Hausheer filed Critical Bionumerik Pharmaceuticals Inc
Priority to JP2002557269A priority Critical patent/JP2004523518A/en
Priority to MXPA03006359A priority patent/MXPA03006359A/en
Priority to AU2002251763A priority patent/AU2002251763B2/en
Priority to CA002434270A priority patent/CA2434270A1/en
Priority to EP02720788A priority patent/EP1351677A4/en
Publication of WO2002056755A2 publication Critical patent/WO2002056755A2/en
Publication of WO2002056755A3 publication Critical patent/WO2002056755A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating patients with cancer that involves administration of a combination regimen of a platinum agent, a taxane agent, and a formula (I) toxicity-reducing agent. The preferred order of administration is the formula (I) compound, followed by the platinum complex, followed by the taxane agent.
PCT/US2002/000943 2001-01-19 2002-01-11 Method for treating cancer WO2002056755A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002557269A JP2004523518A (en) 2001-01-19 2002-01-11 Cancer treatment method with more efficacy and less side effects
MXPA03006359A MXPA03006359A (en) 2001-01-19 2002-01-11 Method for treating cancer having greater efficacy and reduced adverse effects.
AU2002251763A AU2002251763B2 (en) 2001-01-19 2002-01-11 Method for treating cancer
CA002434270A CA2434270A1 (en) 2001-01-19 2002-01-11 Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions
EP02720788A EP1351677A4 (en) 2001-01-19 2002-01-11 Method for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26312701P 2001-01-19 2001-01-19
US60/263,127 2001-01-19

Publications (2)

Publication Number Publication Date
WO2002056755A2 WO2002056755A2 (en) 2002-07-25
WO2002056755A3 true WO2002056755A3 (en) 2002-09-26

Family

ID=23000486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000943 WO2002056755A2 (en) 2001-01-19 2002-01-11 Method for treating cancer

Country Status (6)

Country Link
EP (1) EP1351677A4 (en)
JP (2) JP2004523518A (en)
AU (1) AU2002251763B2 (en)
CA (1) CA2434270A1 (en)
MX (1) MXPA03006359A (en)
WO (1) WO2002056755A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
HUE038768T2 (en) 2005-02-18 2018-11-28 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5694782B2 (en) * 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド Treatment methods and compositions for lung cancer, adenocarcinoma and other medical conditions
WO2009113984A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902610A (en) * 1994-11-14 1999-05-11 Bionumerik Pharmaceuticals, Inc. Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
AU712548B2 (en) * 1996-09-23 1999-11-11 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902610A (en) * 1994-11-14 1999-05-11 Bionumerik Pharmaceuticals, Inc. Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate

Also Published As

Publication number Publication date
AU2002251763B2 (en) 2006-05-04
EP1351677A4 (en) 2009-08-19
JP2004523518A (en) 2004-08-05
JP2009292837A (en) 2009-12-17
EP1351677A2 (en) 2003-10-15
WO2002056755A2 (en) 2002-07-25
CA2434270A1 (en) 2002-07-25
MXPA03006359A (en) 2004-04-20

Similar Documents

Publication Publication Date Title
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
BR0207378A (en) Cancer treatment
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
WO2002053516A3 (en) N(phenylsulphonyl)glycine derivatives and their therapeutic use
WO2003070163A3 (en) Prostacyclin derivatives for treating cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
WO2004045523A3 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
WO2003045494A3 (en) Imiquimod therapies
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
AU2002316771A1 (en) Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
WO2003009803A3 (en) Method of improving cognitive function
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2002056755A3 (en) Method for treating cancer
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
TR200302134T4 (en) Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents.
MXPA03006412A (en) Methods of administering epothilone analogs for the treatment of cancer.
EP1221445A4 (en) Pentacyclic taxane compounds
IL185921A0 (en) A process for the preparation of the 14beta-hydroxy-baccatin iii-1, 14-carbonate
HK1069170A1 (en) A process for the preparation of the 14beta-hydroxy-baccatin iii-1, 14-carbonate
EP1364652A4 (en) Remedies for lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2002720788

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002251763

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434270

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002557269

Country of ref document: JP

Ref document number: PA/A/2003/006359

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002720788

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642